Actipulse Neuroscience GTM brain

Actipulse develops non-invasive neuromodulation devices for clinicians treating psychiatric and neurological conditions, including a proposed home depression treatment.

category

Non-invasive neuromodulation

market profile

  • text: Clinic stimulation providers and emerging at-home devices compete for depression treatment, with distinct technologies and regulatory indications.
  • text: A historical filing describes a home depression pivotal trial and sales in other markets; current status needs confirmation.

personas

  • title: Psychiatrist or neuromodulation clinic director
    pains:
    • Repeated in-clinic treatment can strain clinical capacity and patient access.
    • Needs indication-specific clinical evidence and authorization before adopting a device.
  • title: Health system clinical innovation lead
    pains:
    • Must evaluate safety, training, workflow and reimbursement before introducing a new treatment pathway.
    • Needs evidence that outcomes translate from trials to routine care.
  • title: Patient with major depressive disorder
    pains:
    • Frequent visits can make clinic-based treatment difficult to access.
    • Needs a clinician to assess suitability and available treatment options.

icp

  • text: Psychiatry clinics and physician practices evaluating non-invasive stimulation equipment, historically including customers in Mexico.
  • text: Health systems and research sites studying depression or neurodegenerative disorders; home use depends on jurisdiction and authorization.

message pillars

  • text: Focus on non-invasive brain stimulation for psychiatric and neurological disorders.
  • text: Present research as grounded in clinical and ethical standards.
  • text: Highlight magnetic-pulse transcranial neuromodulation technology.

objections

  • objection: Is the home device authorized and effective for my patient?
    response: Request current jurisdiction-specific authorization, published outcomes and clinician guidance; historical pipeline claims do not establish approval.
  • objection: How will a clinic pay for and implement the device?
    response: Ask for a current quote, reimbursement information, staff training and deployment requirements.

competitors

  • name: BrainsWay
    why: Provides clinical magnetic stimulation systems for depression.
  • name: Neuronetics
    why: Offers clinic-based neuromodulation as an alternative.
  • name: Flow Neuroscience
    why: Offers an at-home depression device using a different stimulation modality.

influencers

  • name: Adrien Châtillon
    url: https://kingscrowd.com/founder-profile-actipulse-neuroscience-adrien-chatillon/
    why: Co-founder discusses the clinical and home-treatment strategy.

keywords

  • non invasive brain stimulation depression
  • home neuromodulation depression
  • TMS clinic equipment
  • magnetic stimulation depression trial
  • depression treatment device
  • brain stimulation psychiatry

voice

  • scientific and clinical
  • mission-led
  • forward-looking

signals

  • text: A psychiatry practice is adding neuromodulation services or evaluating device purchases.
  • text: A research site is pursuing trials in depression or neurodegenerative disease.

pricing

model: unknown

motion

unknown

channels

  • clinical research
  • press
  • LinkedIn

confidence

low

Founders

  • name: Adrien Châtillon
    title: Founder
    role: Founder
    bio: I am a serial entrepreneur (3+ startups), who has lived and worked in more than 8 countries. As the CEO of a medical-tech company, my goal is to democratize access to better and more affordable mental health therapeutics.
  • name: Gabriel Villafuerte
    title: Founder
    role: Founder
    bio: I am a MD/PhD in neuroscience. Passionate about applying technology to solve nervous system disorders. Frustrated (but self-taught!) engineer, industrial designer, and artist.

Back to YC companies